Galapagos NV BRDR G1LP34
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- BRL 6.88
- Day Range
- BRL 6.88–6.90
- 52-Week Range
- BRL 6.88–11.45
- Bid/Ask
- BRL 0.00 / BRL 0.00
- Market Cap
- BRL 453.37 Mil
- Volume/Avg
- 320 / 108
Key Statistics
- Price/Earnings (Normalized)
- 6.69
- Price/Sales
- 0.25
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients’ lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,123
- Website
- https://www.glpg.com
Comparables
Valuation
Metric
|
G1LP34
|
AVIR
|
AKBA
|
---|---|---|---|
Price/Earnings (Normalized) | 6.69 | — | — |
Price/Book Value | 0.03 | 0.60 | — |
Price/Sales | 0.25 | — | 1.10 |
Price/Cash Flow | 0.34 | — | 30.47 |
Price/Earnings
G1LP34
AVIR
AKBA
Financial Strength
Metric
|
G1LP34
|
AVIR
|
AKBA
|
---|---|---|---|
Quick Ratio | 9.55 | 13.11 | 1.03 |
Current Ratio | 9.91 | 13.28 | 1.70 |
Interest Coverage | −43.08 | — | −5.18 |
Quick Ratio
G1LP34
AVIR
AKBA
Profitability
Metric
|
G1LP34
|
AVIR
|
AKBA
|
---|---|---|---|
Return on Assets (Normalized) | 0.69% | −20.62% | −13.51% |
Return on Equity (Normalized) | 1.14% | −21.76% | — |
Return on Invested Capital (Normalized) | −1.45% | −25.76% | −86.71% |
Return on Assets
G1LP34
AVIR
AKBA
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Vertex Pharmaceuticals Inc
VRTX
| Lldszxmy | Qklctw | $124.1 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Vhtxwfjz | Rplsst | $114.2 Bil | |||
Moderna Inc
MRNA
| Ywnbpbklh | Zvrc | $53.7 Bil | |||
argenx SE ADR
ARGX
| Wvfswlb | Thr | $23.0 Bil | |||
BioNTech SE ADR
BNTX
| Tzpdwhdv | Qlk | $22.2 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Kvzmfvx | Tgxbbxc | $20.3 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Vmfgggjp | Wjhzdk | $15.9 Bil | |||
United Therapeutics Corp
UTHR
| Rvylkfy | Cthn | $12.8 Bil | |||
Incyte Corp
INCY
| Zwcnntycw | Mmwckv | $12.2 Bil | |||
Royalty Pharma PLC Class A
RPRX
| Rvwmkmpg | Pbvfbkr | $12.2 Bil |